P1253 Temporal Trend of Opioid Prescriptions Among Adults with Ulcerative Colitis: A Nationwide Cohort Study in Sweden 2008-2021
Authors: Osooli M , Voghera S , Bruze G , Nordenvall C , Myrelid P , Everhov Å H , Ludvigsson J F , Olén O 
Published: January 2025

Abstract

Background
The rising opioid misuse and related mortality led the US government to declare opioid use as a public health emergency in 2017 [1]. Population-based studies on opioid use in Ulcerative Colitis (UC) are scarce [2]. The aim of this study was to describe the time trend of opioid use among adults with UC compared to the general population in Sweden.

Methods
We conducted a nationwide cohort study including individuals aged ≥18 years with a UC diagnosis, identified via two ICD-10 code K51 registrations in the National Patient Register. Each patient with UC was matched with up to 10 reference individuals without inflammatory bowel disease (IBD) by birth year, sex, calendar year, and place of residence. Observation started on January 1, 2008, at age 18, or the date when the UC diagnosis definition was fulfilled (whichever came last) and ended at emigration, death, or December 31, 2021 (whichever came first). Data on opioid dispensations were obtained from the Prescribed Drug Register. Opioid use per calendar year was defined as ≥1dispensed opioid prescription. We categorized codeine combinations, tramadol, and dextropropoxifen opioids as weak and oxycodone, morphine, hydromorphone, fentanyl, buprenorphine, tapentadol, and petidine as strong. Annual prevalence estimates of opioid use were calculated, and joinpoint analysis was performed to explore the trend and to estimate annual percent change (APC) of opioids.

Results
The cohort included 59,983 patients with UC (47.4% female) and 539,505 reference individuals. Cancer diagnoses within two years prior to the index date were observed in 1.1% of UC patients and 0.7% of reference individuals, while psychiatric disorders were identified in 3.8% and 3.6%, respectively. During the observation period, UC patients had a higher prevalence of opioid use compared to reference individuals. The Joinpoint analysis revealed three distinct periods (Figure 1): slightly increasing from 2008-2014, followed by decreasing trends during 2015-2018 (APC: -2.45) and 2019–2021 (APC: -5.20). As shown in Figure 2, the prevalence of any annual opioid use among UC patients declined from 15.5% in 2008 (compared to 9.5% for reference individuals) to 13.0% in 2021 (8.0% for reference individuals). Conversely, strong opioid use among UC patients increased from 3.0% to 9.0% over the study period, compared to a rise from 1.0% to 4.0% among reference individuals.

Conclusion
Opioid use among UC patients in Sweden showed a modestly decreasing trend since 2015 similar to that in the general population. The main limitation of this research was the inability to account for illegal opioid use, which is likely to underestimate the use of opioids among the reference group.

References
1.Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep, 2018. 67(5152): p. 1419-1427.
2.Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2021. 19(5): p. 895-907 e4.